Kyle Leeman

Kyle Leeman has extensive work experience in the pharmaceutical industry. kyle started their career at Pfizer in 1990, where they held the role of Associate Research Fellow for over 27 years. In 2017, they joined Neurocrine Biosciences as the Executive Director of Analytical Development, and during their time there, they played a key role in the development of various analytical techniques. In 2021, they transitioned to Mirati Therapeutics as the VP of Analytical Development and QC, where they continue to contribute their expertise in pharmaceutical analysis and quality control.

Kyle Leeman obtained a Bachelor of Science degree in Chemistry from Quinnipiac University, completing their education between 1986 and 1990.